Gene therapy of established mesothelioma xenografts with recombinant p16(INK4a) adenovirus

Sandra P. Frizelle, Jeff B Rubins, Joan X. Zhou, David T. Curiel, Robert A Kratzke

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


The absence of expression of the p16(INK4a) gene product is observed in virtually all mesothelioma tumors and cell lines, whereas wild-type pRB expression is maintained. We have examined the potential therapeutic role of re-expressing the p16(INK4a) gene product in mice with established human mesothelioma xenografts. Experiments using Adp16 treatments in mesothelioma xenografts demonstrated prolonged survival and potential cure following treatment with p16(INK4a)-based gene therapy. These results demonstrate that p16(INK4a) gene transfer may play a therapeutic role in the treatment of mesothelioma.

Original languageEnglish (US)
Pages (from-to)1421-1425
Number of pages5
JournalCancer gene therapy
Issue number11
StatePublished - 2000

Bibliographical note

Funding Information:
The authors thank Alexander Shar, Ryan Dick, and Jacob Liston for their assistance with animal care. This study was supported by grants from the Minnesota Medical Foundation (R.A.K), the Research Service of the Department of Veterans Affairs (R.A.K), and the National Institutes of Health (D.T.C.) (R01 CA72532; R01 CA74242).


  • Cell cycle
  • Gene therapy
  • Mesothelioma
  • Tumor suppressor
  • p16(INK4a)

Fingerprint Dive into the research topics of 'Gene therapy of established mesothelioma xenografts with recombinant p16(INK4a) adenovirus'. Together they form a unique fingerprint.

Cite this